Video Q&A: What is autism? - A personal view by Martin Raff
Martin Raff trained in Medicine at McGill University and 
was a Resident in Neurology at Massachusetts General 
Hospital when in 1969 he became fascinated by the 
nascent field of cellular immunology and abandoned 
medicine to join the laboratory of Avrion Mitchison at 
Mill Hill, London and subsequently at University College 
London, where he made seminal contributions in the 
biology of T and B lymphocytes. Later, he turned to 
develop mental neurobiology, which occupied him until 
his retirement from active research in 2003.
It was only after his retirement that he became inter­
ested in the biological basis of autism, when it affected 
his own family. In this interview, he talks, as a biologically 
knowledgeable grandparent, about how he sees the disorder 
and where he thinks research on the condition is leading.
Edited transcript
Your research has been in immunology and neural 
development. What got you interested in autism?
I have a grandson who’s autistic, and that’s the immediate 
reason. But I did train in neurology many years ago and 
what’s interesting is that in those three years I never saw 
a patient with autism, which was very rare then. And 
then I was a developmental neurobiologist for 25 years 
and I never heard a talk on autism, even though it was 
thought to be a brain development problem: there wasn’t 
a single talk in 25 years, which is quite remarkable. Now 
autism has increased greatly in prevalence and is 
frequently in the news. But it was my grandson, who is 
now 8, who got me interested in the subject.
What are the defining features of autism?
The three core features are a problem with social inter­
actions, which is often the heart of the matter; a problem 
with language; and a tendency to have restricted interests © 2010 BioMed Central Ltd
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and repeated, stereotypic motor behaviors. That is the so­
called autistic triad, and you need to have two of the 
three and to develop them by the age of 3 to be con­
sidered autistic.
Is autism just one thing? – Isn’t it a spectrum?
It is a spectrum, and probably the reason, or at least one 
important reason, for the apparent increase in autism is 
that the diagnostic criteria have expanded enormously. At 
the bad end of the spectrum are the classic autistic kids, 
and at the best end of the spectrum are Asperger kids, who 
have much less trouble with language and are often very 
smart. But there is also everything in between. I’m sure 
you have many colleagues with some features of autism.
You have an unorthodox view of how autism 
develops – What is it?
I’m not so sure it’s unorthodox. It starts from the need to 
explain the basis of the autistic triad: why do these 
features occur together in this way? Besides the three 
core features, there are also often other associated 
features ­ seizures in 30%, intellectual impairment in 50% 
and behavioral abnormalities such as temper tantrums 
and feeding and sleeping disorders, and so on, which are 
often found in addition to the core triad.
So I think a major question is what binds the core triad 
together? There is no part of the brain that I’m aware of 
where an abnormality would explain this triad while 
leaving so much else intact.
A simple possibility would be that there is a funda­
mental problem in the interaction between the child and 
its parent, usually the mother. It has been known for 
many years that if this interaction is seriously disturbed ­ 
if you can’t achieve what’s called joint attention with your 
mother or care giver ­ then you don’t learn to speak, you 
don’t learn social skills, and you develop restricted 
interests and, not infrequently, repeated stereotypic 
movements.
Is there any evidence for this view?
Yes. If a monkey is separated from its mother and other 
monkeys at birth, it becomes autistic: it doesn’t develop 
normal vocalizations or social skills and shows restricted 
interests and repetitive motor activities such as rocking. 
If a child is born deaf, for example, and it is a year or two 
or three before that’s picked up, the child has an 
increased likelihood of developing autistic features; or if a 
child is born blind and this is missed, that too is often 
associated with autistic features. And children who are 
brought up in orphanages, particularly the big orphan­
ages where you don’t get one­on­one care at all, as occurs 
in some Romanian orphanages, for example, these kids 
often develop what’s called institutional autism. So I 
think it’s pretty clear that if you interfere with the 
child­parent interaction (and other social interactions), 
this can lead to the autistic triad.
Are you saying it’s all the parents’ fault?
Kanner, when he first described autistic behavior in 1943, 
noted in his report that the parents of these children were 
cold and didn’t seem to have an interest in people; you 
can see that he was thinking of blaming the parents. Then 
Bettelheim picked up on the idea and argued that it really 
is the parents’ fault and talked about refrigerator mothers. 
So during the 1950s and 1960s, it was commonly felt that 
autism was an emotional disorder and parents were to 
blame.
Do you think they were wrong?
I think they were right in pointing to the child­parent 
relationship as a problem, but they were pointing to the 
wrong part of the relationship. It is the child that is 
abnormal, largely for genetic reasons. Autism is the most 
genetic of the neuropsychiatric disorders. So the child 
seems genetically impaired in his or her ability to inter­
act, and the question is what is the nature of the impair­
ment. There are lots of ideas about this. One is that 
autistic children don’t process faces normally, which 
inter feres with their interactions with people. Another is 
that they don’t have the special interest in biological as 
opposed to inanimate things that normal children have. 
And another idea is that they can’t figure out what’s going 
on in somebody else’s mind ­ called mind blindness or a 
‘theory of mind problem’.
I think it is very unlikely that any of those are the 
primary problem. I think a more likely explanation is that 
there is a problem with attention ­ a particular type of 
attention problem. There’s increasing evidence that these 
children have what’s called sticky attention, which is a 
problem with attention disengagement. When autistic 
children are focused on something, it’s very hard to 
disconnect them and get them to focus on something 
else. So shifting attention from one thing to another 
seems to be a problem.
Is there evidence for ‘sticky attention’?
I think the best evidence for that comes from Landry and 
Bryson. They published a paper in 2004 on a study of 
5­year­old toddlers ­ 30 autistic, 30 Down syndrome, and 
30 neurotypical, matched for IQ, who were taught to 
focus on an image on a central computer screen. The 
images were just abstract shapes falling through space. 
Then a different abstract image was put up on one of two 
lateral screens, and the child’s eye movements were 
tracked electronically to see how they quickly looked at 
the new image. If the image on the focus screen was 
removed at the same time as the new image was put up, 
the autistic kids performed as well as the other two 




groups, but if the focus image was left on when the new 
image appeared on a lateral screen, then 20% of the 
autistic children didn’t look at the new image at all, and, 
of those that did, many were slow to do so, compared 
with the other two groups. In these experiments, there 
were no people, no faces and no social interactions, 
suggesting a fundamental problem with attention, and, 
specifically, a problem shifting attention from one thing 
to another.
My grandson had this problem in spades. He developed 
quite normally for a year and a half and then, starting 
halfway through his second year, over a period of weeks, 
he dramatically regressed: he stopped looking at you, 
stopped talking, and you could no longer get his attention. 
He could be looking at a wheel spinning or a train going 
round a track or water falling, and you could poke him in 
the arm, flash a light in his eyes, yell in his ears ­ but you 
just couldn’t get his attention. It’s not that he wasn’t paying 
attention ­ he just wasn’t paying attention to you.
There is a lot of interest in the genetic analysis of 
autism - What do you think genetics has to offer?
Well, as I said, it’s the most genetic of the neuropsychiatric 
conditions, and so genetic studies are likely to be the best 
route to understanding the underlying neurobiology. 
There are already about 15 genes that have been 
implicated in autism. At the extremes, there are two 
classes of genetic influences in multifactorial diseases like 
autism. There are polymorphisms, which are common 
genetic variants that increase your risk a bit, usually less 
than 1.5­fold. These are generally identified by genome­
wide association studies using SNPs (single­nucleotide 
polymorphisms) and, for the most part, have not been 
very informative in autism.
The other class consists of rare mutations that greatly 
increase your risk and are much more informative. 
Thomas Bourgeron, for example, was the first to identify 
neuroligin mutations in some individuals with autism. He 
guessed that there might be abnormalities in synapses in 
autism, and so he looked at two genes, neuroligin 3 and 
neuroligin 4, which encode proteins that work only at 
synapses, sequencing the protein­coding regions of these 
genes in more than 100 autistic individuals in multiplex 
families (that is, with 2 or more autistic members), as well 
as in a comparable number of neurotypical individuals. 
He found two Swedish families ­ one with a neuroligin 3 
mutation and the other with a neuroligin 4 mutation: in 
each case, one brother was autistic and the other was 
diagnosed with Asperger syndrome. That was the first 
direct evidence that a mutation that affects a protein that 
works only at synapses can lead to an autism spectrum 
disorder and that the same mutation in the same family 
can lead to both ends of the spectrum. This was a giant 
step forward. Subsequently, mutations in genes that 
encode proteins that interact with neuroligins at 
synapses, including neurexin and shank proteins, have 
been found to predispose to autism and other neuro­
psychiatric disorders. I suspect that synaptic defects may 
be at the heart of the problem in many of these disorders 
and that defects in many different genes can probably 
contribute to different disorders.
There are some single­gene disorders, like Rett’s 
syndrome, fragile X, and tuberous schlerosis, in which 
autism is part of a more complex neurological syndrome. 
These are therefore called syndromic forms of autism. 
There are very good mouse models of these, which are 
proving to be very informative. It seems to me that a 
promising way forward in autism, and in neuropsychiatric 
disorders generally, is to start with a big­effect mutation 
in individuals with the disorder and then try to model the 
disease in an experimental animal such as a mouse. Then 
you can make use of the powerful tools available in mice 
to try to find out what is responsible for the abnormal 
phenotype: which part of the brain, which types of 
neurons, which synapses, and which circuits.
Could the very widely publicized connection 
between vaccination and autism account for the 
increase in incidence?
This of course has been an enormous public concern, 
particularly for parents or grandparents who have autism 
in the family. Interestingly, in the UK the concern is with 
MMR (mumps, measles, rubella) vaccination, whereas in 
the US the concern is with the mercury compound 
(thermasol) in the vehicle.
I should have said earlier that dramatic regression 
occurs in about 30% of autistic kids (although minor 
regression occurs much more commonly): they develop 
apparently normally for a year and then in their second 
year they lose what they had and become classically 
autistic. After that, they may slowly recover to a variable 
extent, and some may recover completely. So you can 
imagine that, if you have a child that’s fine but then, two 
or three weeks after a vaccination, he or she stops looking 
at you and stops talking, it will be difficult to convince 
you that this has nothing to do with the vaccination.
But there have been ten or more studies that show 
pretty unequivocally that vaccination is not involved in 
the autism spectrum disorders. One of the best was from 
Denmark, which showed that the prevalence increased 
about 15­fold from 1990 onwards, yet MMR was 
introduced in Denmark in the 1970s, and thermasol was 
removed in the 1990s with no apparent impact. So I think 
it’s safe to say that vaccination is a red herring. Autism 
spectrum disorders are now recognized to be a fairly 
common condition, affecting almost 1% of children, and 
so there will be a substantial number of coincidences in 
which vaccination seems to trigger the condition.




So the question remains why there has been such a 
large increase since 1990. It is still unclear if there has 
been a real increase, because there are a number of other 
possible explanations that could account for much of the 
increase. One is that the diagnostic criteria have 
broadened enormously since 1990. Another is that 
parents, teachers, and doctors are much more aware of 
autism today than they were before, which is a big factor. 
Another is that, in the 1990s in America, many states 
provided special educational support for autistic children, 
so that parents were keen to have the diagnosis confirmed 
to take advantage of these services, which no doubt 
contributed to the increased prevalence, as well as to a 
decrease in the stigma associated with autism, which, in 
itself, would greatly increase the number of diagnoses.
To go back to genetics - How do you get from a 
rare mutation to the cause of the disorder in the 
common cases?
Now that you can sequence DNA increasingly cheaply 
and quickly, it is feasible to sequence the genomes of 
large numbers of autistic individuals, which almost 
certainly will uncover increasing numbers of rare, big­
effect mutations that contribute to the disorder. Once 
such a mutation is identified, one can try to produce the 
condition, or a part of it, in an experimental animal such 
as a mouse, where you can analyze the neurobiological 
basis of the problem. Once this has been done, which 
could take years, it will be necessary to go back to the 
humans with the same genetic problem to find out if the 
same cells, the same brain regions, the same synapses, 
and so on are involved.
One way to do this is to make induced pluripotent stem 
cells (iPSCs) ­ first from the mouse and then from autistic 
individuals with the same genetic problem. iPSCs closely 
resemble ES (embryonic stem) cells, in that they can 
proliferate indefinitely in culture and be induced to 
differentiate into almost any type of cell in the body, 
including into different types of neurons. Fortunately, 
developmental neurobiologists are rapidly figuring out 
how to get many different types of neurons from such 
pluripotent stem cells. Once you have figured out how to 
get the appropriate types of neurons, you can let them 
form the synapses and circuits, either in a culture dish or 
after transplantation into a developing mouse brain, to 
show that you can reproduce the physiological defects 
that you found in the mouse mutant. Then you would be 
ready to produce iPSCs from the autistic humans and use 
what you had learned studying the mouse iPSCs about 
how to produce the relevant types of neurons, synapses, 
and circuits that you think are affected, to see if you can 
reproduce the same type of physiological abnormalities. 
If you succeed, you can screen for drugs that can correct 
the problem and see if they can ameliorate the clinical 
problem. All of this will be difficult and very time­
consuming, and it may not work, but, if it did, the payoff 
could be great, both in terms of new drugs and what it 
could potentially tell us about how the normal human 
brain works. I am optimistic, especially as many of the 
mouse models of the syndromic forms of autism have 
been shown to be at least partially reversible by 
treatments given to adult mice; this suggests that many of 
the clinical problems may result from reversible 
functional defects in the adult brain, rather than from 
irreversible anatomical defects that many believed to be 
the problem.
Where can I find out more?
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